Efficacy and Safety of Everolimus in Metastatic Gastroenteropancreatic Neuroendocrine Tumors Abstract #479

Introduction: Everolimus is a treatment option for patients with pancreatic NETs, while its use in patients with gastrointestinal NETs still remains to be defined.
Aim(s): To test the efficacy and side effects of Everolimus in six patients with differentiated NET refractory to other therapies.
Materials and methods: Everolimus (10 mg/day; compassionate use) was administered until disease progression or unacceptable toxicity. Three patients had metastases of ileal neuroendocrine carcinoma; one of typical lung carcinoid; one of ovary carcinoid and one of pancreatic insulinoma.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Professor Maria Rosaria Ambrosio

To read results and conclusion, please login ...

Further abstracts you may be interested in

#483 Efficacy of Everolimus in Patients with Metastatic Insulinomas and Refractory Hypoglycemia: For the French Group of Endocrine Tumors (GTE-Renaten)
Introduction: Refractory hypoglycemia in patients with metastatic insulinomas (RHMI) is an important cause of morbidity and mortality and Everolimus could be a new therapeutic option.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Miss Valérie Bernard
#1525 Retrospective Review of Single Centre’s Experience of the Side Effects Reported by Patients Receiving Everolimus and the Potential Implications Relating to Patient Monitoring and Education
Introduction: Everolimus, an mTOR inhibitor, is a recommended therapy for patients with pancreatic neuroendocrine tumours. It has recognised toxicity profile.
Conference: 13th Annual ENETS conference (2016)
Category: Medical treatment - Targeted therapies
Presenting Author: Philippa Davies
Authors: Davies P, ...
#2203 A Case of Rectal Abscess Emerged Immediately after Starting Chemotherapy with Everolimus and Required Surgical Drainage
Introduction: <Introduction>Everolimus is widely used for unresectable panNET. For its efficacy as an immunosuppressant, infectious adverse events are well-known.
Conference: 15th Annual ENETS conference (2018)
Category: Case reports
Presenting Author: Kenzo Nakano
Authors: Nakano K, Masui T, Yogo A, Uchida Y, ...
#425 Successful Treatment with Everolimus of Functioning Liver Metastases From a Pancreatic Insulinoma
Introduction: Medical treatment of metastatic insulinoma is debated.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Dr Maria Chiara Zatelli
#503 Long-Term Stable Disease with Everolimus in a Patient with Advanced Pancreatic Neuroendocrine Tumor Enrolled in RADIANT-1
Introduction: The phase II open-label RADIANT-1 study evaluated the safety and efficacy of Everolimus (E, 10 mg/d) ± octreotide LAR (O) in patients (pts) with advanced pancreatic neuroendocrine tumors (pNET) after chemotherapy failure. Objective tumor response was 9.6% in the E group and 4.4% in the E+O group (all partial), and stable disease (SD) was 68% and 80%.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Jenny Falkerby